How deadly is Alzheimer?

['Səmɣar tabrat ten']

Alwaq wa id Alzheimer eqqal a eqqalan a hinan?

Aṭṭanen n Alzheimer eqqal aśuhu n əšiɣil n əšiɣil wa itaj in əšiɣilan ən əšəɣil ad aɣin, awa itaj in aśuhu ən əšəɣil ən asəmutiy, aniyat əd əšiɣil ən amedran.

Eqal eɣaf wa ojjaran n dementia, eqqal i 60-80% n haratan fuk

Aṭṭan wen eqqal aśohen, id azzaman n tamudre darat amiyiz amos 4-8 n awatay, kuddeɣ as addinat iyyad addoben ad iddar har 20 n awatay id aṭṭan

Iddikud n tamattant n Alzheimer disease izlay daɣ teɣare d ichaɣib wa s ijja akayad

Daɣ Alzheimer's Association, aṭṭanen n Alzheimer eqqal s data s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data eqqal s data

Daɣ awatay wan 2019, aśahat wan Alzheimer eqal atiwasanan sund ašəɣəl wa ezzaran ən tamattant ye 121,9444 n addinat daɣ États-Unis.

Eqal assohen ad akayad as iddikud n tamattant n Alzheimer war eqqal fal aṭṭan iman net mucham har ajjudi fal aśuhu d isuj n assexat iyyad id izjaranen fal aṭṭan

Alwaq wa id aṭṭanen itaj, addinat addoben ad afen uguren daɣ alxidmaten n tamudre n alwaq fuk chund tet, aɣummu d asuj, addoben ad awin s asuj, aśuhu d aśuhu n aśahat iyyad

Daɣ asiwad, addinat ilan aśahat ən Alzheimer addoben ad aqilan dǎɣ asukni ogaran ən aśahat ən aśahat, pneumonia, əd iyad aśahatnen.

Kuddeɣ as war t illa asafar i aṭṭan wan Alzheimer, illan isuj illanen addoben ad afhamanen ad issiwaden i awikkal n samalan tolas ad issiwaden i tamudre

Umaɣ eqqal a fal ittimɣur asafar eynaynen tolas daɣ samando n afanaz i aśahat wen aśohatnen

['Isalan wi illanen']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Zhu B, Chen X, Li W, Zhou D: Effect of Alzheimer Disease on Prognosis of Intensive Care Unit (ICU) Patients: A Propensity Score Matching Analysis. Med Sci Monit. 2022, 28 (): e935397.

Almeida MC, Gomes Cde M, Nascimento LF: Spatial distribution of deaths due to Alzheimer's disease in the state of São Paulo, Brazil. Sao Paulo Med J. 2014, 132 (4): 199-204.

Aevarsson O, Svanborg A, Skoog I: Seven-year survival rate after age 85 years: relation to Alzheimer disease and vascular dementia. Arch Neurol. 1998, 55 (9): 1226-32.

Mortality from Alzheimer disease--United States, 1979-1987. MMWR Morb Mortal Wkly Rep. 1990, 39 (43): 785-8.

Breitner JC: Clinical genetics and genetic counseling in Alzheimer disease. Ann Intern Med. 1991, 115 (8): 601-6.

Iulita MF, Garzón Chavez D, Klitgaard Christensen M, Valle Tamayo N, Plana-Ripoll O, Rasmussen SA, Roqué Figuls M, Alcolea D, Videla L, Barroeta I, Benejam B, Altuna M, Padilla C, Pegueroles J, Fernandez S, Belbin O, Carmona-Iragui M, Blesa R, Lleó A, Bejanin A, Fortea J: Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome. JAMA Netw Open. 2022, 5 (5): e2212910.

['Asukni: medikal']

['Web site wen eqqal i isalan n teɣare d isalan ɣas tolas war eqqel asiwil n asafar meɣ alxidmat tan n musnat']

['Isalan wi ikfan war addoben ad axdaman i asifham meɣ asafar n aśahat meɣ aśahat tolas wi aramanen asiwil n asafar n awadim ilzam ad aruman asiwil n asafar n awadim']

['Dǎɣ asikin, neural net wa iknanen tirmawen ən assestan, eqal aśohen aśohat dǎɣ alwaq wa id itawan dǎɣ maɗin ən maɗinan. sund, iddikud ən adinat wi atiwasananen as aśohat atiwasanan.']

['Harkuk arha majrad n doctor inek meɣ n awadim n assexat n tazmert n addinat fal aśahat n aśahat. War t-id-t-igdel majrad n aśahat n awadim meɣ azzaman daɣ aśahat fal as harat awa iktabem fal site wen. Afal as ad t-illa aśahat n aśahat n aśahat, asiwel 911 meɣ aru s ehan n aśahat n aśahat wa oharnen daɣ azzaman. War t-illa majrad n aśahat n awadim d aśahat fal site wen meɣ axadam net. BioMedLib meɣ inaxdiman net meɣ awadim wa iknanen fal site wen, war t-illa majrad, iknan meɣ iknan, fal isalan wi dawanen meɣ axadam net']

['Asukni: copyright']

['Digital Millennium Copyright Act wan 1998, 17 U.S.C. § 512 (DMCA) eha almaɣna i kel alxaq n alxaq n alxaq wa allaɣen as isuj win illanen fal Internet ikna alxaq nasan daɣ achareɣa n alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq']

['A fal tazamt s tiditt as isalan meɣ isuj win illanen daɣ asuj n asuj net meɣ alxidmaten iknan alxaq inek n alxaq, addobat ad aɣ-d-tazneḍ (meɣ agent inek) isalan meɣ isuj win ad n-ikkes meɣ ad n-isikkid alxidmat']

['Isalan ilzam ad ittusiknan s eɣaf s email (ikayad edag "Contact" i tansa n email)']

['DMCA t-assirɣas as isalan inek n asiwad n alxaq n alxoriya eha isalan win: (1) almaɣna n alxidmat eha alxaq n alxoriya eqqal harat n asiwad eha alxaq n alxoriya; (2) almaɣna n almaɣna eha alxoriya d isalan ajjotnen ijjan aɣ ad n afhaman almaɣna; (3) isalan n alɣisab inek, ahan tansa, amaṭṭaf n tilifun d tansa n email inek; (4) almaɣna inek n as ilan tumast n alxaq n alxoriya as almaɣna wa s eha alxaq eha alxaq eha alxaq war eha alxaq n alxaq eha alxoriya meɣ amatikki net meɣ s alxidmat n achareɣa fuk']

['(5) almaɣna n awen, iktab daɣ azruf n alkad n tiditt, as isalan win isalan aqqalan tiditt tolas ilan tanaya n as artay alxaqqan win alxakum wi s allaɣen as ikna']

['Dǎɣ awa, əmik ən əmik ən alxaq meɣ awadim ən alxaq ən alxaq meɣ awadim atiwafan ye igi ən alxaq ən alxaq.']

['A fal war t-id-t-id-t-id-t-id-t-id-t-id-t-id-t-id-t-id-t-id-t-id-t-id-t-id-t-id-t-id-t-id-t-id-t-id-t-id-t-id-t-id']

['Assahat']

['Ilzam aɣ e-mail s asteqsi meɣ asukni']

How deadly is alzheimer?

Alzheimer's disease is a progressive neurological disorder that causes brain cells to degenerate and die, leading to a decline in memory, thinking, and reasoning skills.

It is the most common cause of dementia, accounting for 60-80% of all cases.

The disease is ultimately fatal, with the average life expectancy after diagnosis being 4-8 years, although some people can live up to 20 years with the disease.

The mortality rate for Alzheimer's disease varies depending on the study and the population being examined.

According to the Alzheimer's Association, Alzheimer's disease is the sixth leading cause of death in the United States, and it is the fifth leading cause of death for those aged 65 and older.

In 2019, Alzheimer's disease was reported as the underlying cause of death for 121,9444 people in the United States.

It is important to note that the mortality rate for Alzheimer's disease is not solely due to the disease itself, but also due to complications and other health issues that arise as a result of the disease.

As the disease progresses, individuals may experience difficulty with activities of daily living, such as eating, bathing, and dressing, which can lead to malnutrition, infections, and other health problems.

Additionally, individuals with Alzheimer's disease may be at an increased risk of falls, pneumonia, and other infections.

While there is currently no cure for Alzheimer's disease, there are treatments available that can help manage symptoms and improve quality of life.

Research is ongoing to develop new treatments and ultimately find a cure for this devastating disease.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.